What is the recommended treatment for tinea corporis?

Treatment for Tinea Corporis

First-Line Treatment: Topical Antifungals for Localized Disease

For localized tinea corporis, topical antifungal therapy is the first-line treatment, with oral therapy reserved for extensive infections, treatment failures, or immunocompromised patients. 1

Specific Topical Regimens

• Terbinafine 1% cream applied once daily for 7 days is highly effective, achieving 84.2% mycological cure rates in clinical trials 2
• Clotrimazole 1% cream applied twice daily for 2-4 weeks provides mycological cure rates approximately 2.9-fold higher than placebo 3
• Miconazole cream applied twice daily for 2-4 weeks is an alternative option for mild to moderate disease 3
• Naftifine 1% demonstrates superior mycological cure compared to placebo (RR 2.38), though evidence quality is lower 4

When Topical Therapy Fails

• Failure of appropriate topical therapy after 2-4 weeks indicates the need to switch to systemic antifungal treatment 3
• Extensive, multiple, deep, recurrent, chronic, or immunocompromised patient presentations require oral therapy from the outset 5

Oral Antifungal Therapy for Extensive or Refractory Disease

First-Line Oral Options

Terbinafine and itraconazole appear equally effective and safe for treating tinea corporis. 6

Terbinafine

• Dosing: 250 mg once daily for 1-2 weeks 3, 7
• Advantages: Potent fungicidal properties, minimal drug interactions, fewer side effects compared to other oral antifungals 6
• Particularly effective against Trichophyton tonsurans infections 3
• Tolerability: Gastrointestinal upset or rash occurs in fewer than 8% of patients 3
• Monitoring: Baseline liver function tests recommended, especially with pre-existing hepatic abnormalities 3

Itraconazole

• Dosing: 100 mg once daily for 15 days, achieving 87% mycological cure rate 3
• Alternative dosing: 200 mg daily for 7 days 7
• Licensing: Approved for children older than 12 years in the United Kingdom 3
• Drug interactions: Enhanced toxicity with warfarin, certain antihistamines (terfenadine, astemizole), antipsychotics, midazolam, digoxin, and simvastatin; reduced efficacy with H₂-blockers, phenytoin, and rifampicin 3
• Superior to griseofulvin: 87% vs 57% mycological cure rate 3

Second-Line Oral Option

Fluconazole

• Dosing: 50-100 mg daily for 2-3 weeks, or 150 mg once weekly for 2-3 weeks 7, 3
• Limitations: Not licensed for tinea in children under 10 years in the UK, less cost-effective than terbinafine with limited comparative efficacy data 3
• Use as third-line option when other agents have failed 3

Critical Pitfall: Avoid Antifungal-Corticosteroid Combinations

• Do not use combination antifungal-corticosteroid products as monotherapy, despite 7-10% of patients receiving these in practice 8
• While combinations show slightly higher clinical cure rates than azoles alone, there is no statistically significant difference in mycological cure 4
• Corticosteroids can mask symptoms and potentially worsen infection 5

Treatment Monitoring and Success Criteria

Defining Treatment Success

• Mycological cure (negative microscopy/culture) is the definitive endpoint, not merely clinical improvement 1, 3
• Repeat mycological sampling is required until clearance is documented 1
• Clinical appearance alone should not guide discontinuation decisions 9

Diagnostic Confirmation

• Obtain specimens via scalpel scraping from the active border of the lesion before initiating treatment 3, 5
• Potassium hydroxide (KOH) wet-mount preparation provides rapid confirmation 5
• Fungal culture is the gold standard, especially for widespread, severe, or treatment-resistant infections 5
• Dermoscopy is a useful non-invasive diagnostic tool when diagnosis is uncertain 5

Prevention and Contact Management

Preventing Recurrence and Transmission

• Screen and treat all household members when infection is caused by anthropophilic species like Trichophyton tonsurans, as over 50% of family members may be affected 3
• Clean all fomites (hairbrushes, combs, towels) with disinfectant or 2% sodium hypochlorite solution 3
• Avoid skin-to-skin contact with infected individuals 3
• Do not share towels and other personal items 3
• Cover lesions to prevent transmission 3

School and Work Attendance

• Children receiving appropriate antifungal therapy may continue attending school; exclusion is unnecessary once treatment has started 3

Emerging Resistance Concerns

• Rising resistance of dermatophytes to terbinafine and itraconazole is becoming a significant public health concern 6
• Trichophyton indotineae exhibits terbinafine resistance and is increasing in frequency 6
• Trichophyton mentagrophytes genotype VII (now T. interdigitale) is gaining importance due to increasing frequency and severity 6
• Diagnostic testing is underutilized (<10% of patients receive testing), limiting ability to detect resistance patterns 8

Treatment Algorithm Summary

1. Localized disease: Start with topical terbinafine 1% cream once daily for 7 days 2
2. If topical fails after 2-4 weeks: Switch to oral terbinafine 250 mg daily for 1-2 weeks 3, 7
3. Extensive/multiple lesions at presentation: Begin oral terbinafine 250 mg daily for 1-2 weeks 3
4. If terbinafine contraindicated or fails: Use itraconazole 100 mg daily for 15 days 3
5. Refractory cases: Consider fluconazole 150 mg weekly for 2-3 weeks 3
6. Always: Confirm mycological cure before discontinuing treatment 1
7. Always: Screen and treat household contacts for anthropophilic species 3